0 CHECKOUT

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2015

  • ID: 3500396
  • October 2015
  • 101 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Apotex, Inc.
  • Genexine, Inc.
  • Myelo Therapeutics GmbH
  • Pfenex Inc.
  • Richter Gedeon Nyrt.
  • UAB Profarma
  • MORE

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2015

Summary

The report ‘Chemotherapy Induced Neutropenia - Pipeline Review, H2 2015’, provides an overview of the Chemotherapy Induced Neutropenia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Neutropenia and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Apotex, Inc.
  • Genexine, Inc.
  • Myelo Therapeutics GmbH
  • Pfenex Inc.
  • Richter Gedeon Nyrt.
  • UAB Profarma
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Chemotherapy Induced Neutropenia Overview

Therapeutics Development

Pipeline Products for Chemotherapy Induced Neutropenia - Overview

Pipeline Products for Chemotherapy Induced Neutropenia - Comparative Analysis

Chemotherapy Induced Neutropenia - Therapeutics under Development by Companies

Chemotherapy Induced Neutropenia - Therapeutics under Investigation by Universities/Institutes

Chemotherapy Induced Neutropenia - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Chemotherapy Induced Neutropenia - Products under Development by Companies

Chemotherapy Induced Neutropenia - Products under Investigation by Universities/Institutes

Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development

Apotex, Inc.

Biogenomics Limited

Bolder Biotechnology, Inc.

Cellerant Therapeutics, Inc.

Chong Kun Dang Pharmaceutical Corp.

Dr. Reddy's Laboratories Limited

Generon (Shanghai) Corporation Ltd.

Genexine, Inc.

Hanmi Pharmaceuticals, Co. Ltd.

Hospira, Inc.

Myelo Therapeutics GmbH

Octapharma AG

Pfenex Inc.

Pfizer Inc.

PharmaEssentia Corporation

Reliance Life Sciences Pvt. Ltd.

Richter Gedeon Nyrt.

Sandoz International GmbH

UAB Profarma

USV Limited

Welichem Biotech Inc.

Chemotherapy Induced Neutropenia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

BBT-007 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BBT-015 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BBT-018 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

EC-18 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

eflapegrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

F-627 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GW-003 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GXG-3 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Myelo-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Recombinant Protein for Chemotherapy Induced Neutropenia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

romyelocel-L - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TXA-302 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

WBI-2100 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Chemotherapy Induced Neutropenia - Recent Pipeline Updates

Chemotherapy Induced Neutropenia - Dormant Projects

Chemotherapy Induced Neutropenia - Discontinued Products

Chemotherapy Induced Neutropenia - Product Development Milestones

Featured News & Press Releases

Dec 08, 2014: Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at the American Society of Hematology 56th Annual Meeting at San Francisco

Sep 09, 2014: Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm

May 28, 2014: Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor to Treat Chemotherapy-induced Neutropenia

Apr 08, 2013: Spectrum Pharma Initiates Phase II Study Of Long-acting GCSF Drug Candidate SPI-2012 For Treatment Of Chemotherapy-induced Neutropenia

Jan 07, 2013: Generon Initiates Phase I/II Clinical Trial Of F-627 For Treatment Of Breast Cancer In China

May 10, 2011: Dr Reddy’s Launches Pegfilgrastim In India Under Brand Name Peg-grafeel

Mar 22, 2011: Cellerant Initiates Phase I/II Clinical Trial Of CLT-008 For Chemotherapy Induced Neutropenia In Acute Leukemia Patients

Dec 08, 2010: Generon Presents Poster On F-627 At 52nd Annual Meeting Of American Society Of Hematology

Nov 22, 2010: Generon Completes Dosing In Phase I Study Of F-627 In Australia

Nov 03, 2010: Bolder BioTechnology Announces $1.2 Million In Qualifying Therapeutic Discovery Project Grants

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2015

Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Comparative Analysis by Unknown Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2015

Chemotherapy Induced Neutropenia - Pipeline by Apotex, Inc., H2 2015

Chemotherapy Induced Neutropenia - Pipeline by Biogenomics Limited, H2 2015

Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology, Inc., H2 2015

Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H2 2015

Chemotherapy Induced Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015

Chemotherapy Induced Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015

Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2015

Chemotherapy Induced Neutropenia - Pipeline by Genexine, Inc., H2 2015

Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015

Chemotherapy Induced Neutropenia - Pipeline by Hospira, Inc., H2 2015

Chemotherapy Induced Neutropenia - Pipeline by Myelo Therapeutics GmbH, H2 2015

Chemotherapy Induced Neutropenia - Pipeline by Octapharma AG, H2 2015

Chemotherapy Induced Neutropenia - Pipeline by Pfenex Inc., H2 2015

Chemotherapy Induced Neutropenia - Pipeline by Pfizer Inc., H2 2015

Chemotherapy Induced Neutropenia - Pipeline by PharmaEssentia Corporation, H2 2015

Chemotherapy Induced Neutropenia - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2015

Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt., H2 2015

Chemotherapy Induced Neutropenia - Pipeline by Sandoz International GmbH, H2 2015

Chemotherapy Induced Neutropenia - Pipeline by UAB Profarma, H2 2015

Chemotherapy Induced Neutropenia - Pipeline by USV Limited, H2 2015

Chemotherapy Induced Neutropenia - Pipeline by Welichem Biotech Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Chemotherapy Induced Neutropenia Therapeutics - Recent Pipeline Updates, H2 2015

Chemotherapy Induced Neutropenia - Dormant Projects, H2 2015

Chemotherapy Induced Neutropenia - Dormant Projects (Contd..1), H2 2015

Chemotherapy Induced Neutropenia - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2015

Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Apotex, Inc.
Biogenomics Limited
Bolder Biotechnology, Inc.
Cellerant Therapeutics, Inc.
Chong Kun Dang Pharmaceutical Corp.
Dr. Reddy's Laboratories Limited
Generon (Shanghai) Corporation Ltd.
Genexine, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Hospira, Inc.
Myelo Therapeutics GmbH
Octapharma AG
Pfenex Inc.
Pfizer Inc.
PharmaEssentia Corporation
Reliance Life Sciences Pvt. Ltd.
Richter Gedeon Nyrt.
Sandoz International GmbH
UAB Profarma
USV Limited
Welichem Biotech Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.